The medical cannabis industry is growing rapidly in Europe and thousands of patients are already prescribed with cannabis-based drugs. This created a new demand that now runs the risk of being unsatisfied if the legislation remains fragmented amongst EU countries.
Several decision-makers and stakeholders are calling on the European Commission to investigate which kind of regulatory measures at the EU level should be put in place to meet patients’ needs.
Standards, safety, ethics and sustainability are the topics to discuss further when it will be time to draft guidelines and pieces of regulation with the aim of creating a regulatory environment for patients and investors.
The European Medicinal Cannabis Association (EUMCA), the newly formed Brussels-based industry body, represents the interests of ethical companies working in the supply and manufacturer of medicinal cannabis.
Germany's regulatory approach to medical cannabis is good practice and should be replicated across Europe, according to newly-born European Medicinal Cannabis Association (EUMCA).
A strong EU regulatory framework on medical cannabis is needed to provide investors with stability but also to give peace of mind to patients struggling with fragmented legislation among member states, socialist MEP Miriam Dalli said.
Patients deserve faster access to safe medical cannabis. Legalization is not enough – governments and businesses need to work together to reduce barriers and lessen patients’ reliance on the illicit market.